“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are involved in a ...
Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options become available this week, for the April 2026 expiration. One of the key inputs that goes into the price an option buyer is ...